Leader

Sex hormone modulation in systemic lupus erythematosus: still a therapeutic option?

The influence of sex hormones on the immune system and the marked difference in the prevalence of specific autoimmune diseases between the two sexes have long been recognised. Women are affected much more than men by diseases of the immune system, particularly systemic lupus erythematosus (SLE), the prototype 'autoimmune' disease. Systemic lupus erythematosus is most prevalent in the childbearing years with a female: male sex incidence of 9:1. This female to male ratio is much reduced in prepubertal children and after the menopause. 

Menstruation may be associated with adverse symptomatology in 60% of lupus patients and seems to be limited to the 10 days immediately before the start of bleeding. Increased joint pains, fevers, malaise, and behaviour disturbances may be noted. During pregnancy, and especially in the puerperium, 'flares' of the disease may also occur.

The use of conjugated symmetric oestrogens for birth control may also be associated with such 'flares', and it has been suggested that oral contraceptives may be associated with the development of such complications as chorea and thromboembolism in some subjects with autoimmune disorders, particularly in the subset of systemic lupus erythematosus with antiphospholipid antibodies. Hormonal studies in lupus patients have shown that patients of both sexes have raised concentrations of 16α-hydroxyoestrone, while women, additionally, have increases of oestradiol. A compensatory decrease in catechol and 2-hydroxylated oestrogens has also been noted.

How these hormones modulate the immune response is unclear, but several differing mechanisms may interact. There may be a relation with steroid receptors: sex steroid receptors have been found on the thymus and oestrogen receptors are localised specifically to the OKT8+ (suppressor/cytotoxic) subset of T cells.

Genetically induced hyperoestrogenicity found in men with the Klinefelter's syndrome may also perhaps be important in the development of systemic lupus erythematosus, as well as rheumatoid arthritis in these patients, and a role for the X chromosome in pathogenesis has been suggested.

In addition to oestrogen abnormalities, studies of androgen metabolism in systemic lupus erythematosus have shown that the oxidation of testosterone at C-17 is increased only in women with active disease.

Data suggest that there are fundamental differences in sex steroid metabolism in systemic lupus erythematosus, particularly in women with active disease, and these findings prompted the use of compounds with potent antioestrogen or proandrogenic effects in the control and treatment of the condition.

Treatment

**ANDROGENS**
Androgenic substances have proved disappointing as modulators of human systemic lupus erythematosus, either because of lack of therapeutic effects or because of unacceptable side effects. Two such compounds have been tried over the past few years, both weak androgens with anabolic properties: nandrolone decanoate and danazol.

**Nandrolone decanoate** (19-nortestosterone decylate), although effective in NZB/NZW mice, had no demonstrable clinical effects when used on eight female patients with systemic lupus erythematosus.

Recent data on the use of synthetic androgens like 19-nortestosterone in the treatment of male lupus patients has shown that their use results in overall worsened disease (Lahita R, personal communication). The apparent exacerbation of the disease in these men coincides with a lowered free testosterone and low luteinising hormone concentration. The latter indicates that nandrolone is a potent androgen, suppressing free testosterone secretion, and that this effect may be associated with a worsened disease in men as the clinical course of the disease did not correlate with laboratory data (Lahita R, unpublished data).

**Danazol**, a heterocyclic steroid related clinically to 17α-ethinyltestosterone, has antigonadotropic effects, suppressing follicle stimulating hormone and luteinising hormone. It was ineffective in murine lupus in one study, but there was considerable clinical improvement in seven women with mildly active systemic lupus erythematosus and in two with premenstrual exacerbations in another study.

Danazol has been shown to be effective in patients with hereditary angioedema resulting in increased levels of C1 esterase inhibitor and fewer clinical episodes. It has also been found to be effective in the clinical control of facial rash of systemic lupus erythematosus in a patient with hereditary angioedema. Donaldson and Hess reported the use of danazol 200 mg daily in a similar patient with marked sun sensitivity and 'butterfly' lesions on the face, which resulted in disappearance of the rash and resistance to the normally harmful effects of solar exposure.

In a male patient, however, use of this compound was associated with a 'flare' of his disease, accompanied by dramatic reductions in his testosterone concentrations. The
authors concluded that danazol treatment is analogous to castration. It suppressed endogenous androgen production but failed to provide sufficient exogenous androgen. In women, however, danazol suppresses endogenous oestrogen activity and would therefore be expected to produce improvement for this reason.

Thrombocytopenia associated with systemic lupus erythematosus seems to be particularly responsive to this compound and several studies have demonstrated improvement, with remissions lasting from two to 13 months.29 30

SYNTHETIC HYDROXYPROGESTERONE DERIVATIVES: CYPROTERONE

Cyproterone, also possessing antiandrogentic properties by suppressing ovulation, depresses ovariian oestrogen secretion, thus acting as an oral contraceptive.31-33 It has antiandrogenic effects, on the skin mainly, and antisyndromic effects on liver and kidney.34 It has been widely used to treat acne and hirsutism. It was given to seven female patients with moderately active systemic lupus erythematosus,35 and no significant side effects were noted by any patients. The number of clinical exacerbations of systemic lupus erythematosus was lower during cyproterone treatment (27 lupus 'flares' before treatment over 156 patient-months compared with 15 'flares' during 170 patient-months with cyproterone treatment), only one patient experiencing a severe 'flare' with glomerulonephritis and nephrotic syndrome after 21 months of cyproterone treatment. The effect on mouth ulceration, particularly, was dramatic—steroid dose and maintenance dosage of hydroxychloroquine were both reduced. The plasma follicle stimulating hormone and luteinising hormone were significantly decreased, with marked decreases in oestradiol concentrations, whereas no effect on male hormone concentrations was seen. Anti-dsDNA levels and C3 and C4 complement concentrations were not altered.

It is always interesting to discuss the possible therapeutic use of new agents in the treatment of disease, and hormones are the most readily available and best studied of all the immunomodulatory substances known to man. The major problem is simply that the basic immunological effects of these agents in the diseased host are not known and still require extensive investigation. The effects of such agents in the postmenopausal patient with immune disease and the judicious use of birth control agents are beyond the scope of this editorial, but clearly these are important questions which beg answers.

It is likely that appropriate sex steroid therapy with newer compounds presently under development may become useful, adjunctive treatment for lupus patients in the future.

Gender is important, in both the presentation and modulation of autoimmune disease, especially the disease lupus.
Sex hormone modulation in systemic lupus erythematosus: still a therapeutic option?

R A Asherson and R G Lahita

doi: 10.1136/ard.50.12.897

Updated information and services can be found at:
http://ard.bmj.com/content/50/12/897.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/